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ABSTRACT 26 
Chitosan is a polymer obtained by partial chitin N-deacetylation with antifungal action. 27 
This compound causes plasma membrane permeabilization in sensitive filamentous 28 
fungi and yeast. Previous studies have established that membrane fluidity together with 29 
cell energy are key factors determining chitosan sensitivity in fungi. A five-fold joint 30 
reduction of both glucose (main carbon (C) source) and nitrogen (N) increased 2-fold 31 
Neurospora crassa sensitivity to chitosan. We were able to link this chitosan sensitivity 32 
increase due to nutrient (C and N) limitation to an intracellular production of reactive 33 
oxygen species (ROS) and to plasma membrane permeabilization. Very low chitosan 34 
concentrations (2.5 µg ml-1), in low C (0.8 g l-1) and low N (0.03 g l-1) containing 35 
growth medium, caused a partial membrane permeabilization and a 25% growth 36 
reduction of N. crassa. Increasing chitosan concentration led to full membrane 37 
permeabilization and subsequent cell death. Releasing N. crassa from C and N 38 
limitation reduced chitosan antifungal activity in spite of high ROS intracellular levels. 39 
When lactate was used instead of glucose, C and N limitation increased N. crassa 40 
sensitivity to chitosan to a larger extent (ca. 4-fold) than what glucose did. Limitation of 41 
C and N also increased sensitivity of filamentous fungi and yeast human pathogens to 42 
chitosan. For Fusarium proliferatum, lowering 100-fold C and N content in the growth 43 
medium, increased 16-fold chitosan sensitivity. Similar results were found for Candida 44 
albicans, C. krusei (fluconazole resistant) and Cryptococcus spp.  Severe C and N 45 
limitation increased chitosan antifungal activity for all pathogens tested. Chitosan at 100 46 
µg ml-1 was lethal for 8 out of 10 fungal human pathogens tested but was not toxic to 47 
HEK293 (human) and COS7 (monkey) cell lines. Besides, with intermediate C and N 48 
levels, chitosan (100 µg ml-1) increased 90% survival of Galleria mellonella larvae 49 
infected with C. albicans at 24 h post-inoculation respect to controls with no chitosan. 50 
These results are of paramount importance for the development of chitosan as an 51 
antifungal compound for practical use.  52 
 53 
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1 Introduction 57 
Chitosan is a polymer obtained by partial chitin N-deacetylation (Kumar, 2000) with 58 
antifungal action (Allan and Hadwiger, 1979). Many filamentous fungi (including 59 
Neurospora crassa) and yeast are sensitive to chitosan (Palma-Guerrero et al., 2009; 60 
Jaime et al., 2012). However, chitosan antifungal activity differs within fungal groups 61 
(Palma-Guerrero et. al 2008). Filamentous fungi and yeast human infections are a 62 
highly relevant health issue in our society (Richardson and Lass-Flörl, 2008; Miceli et 63 
al., 2011). These fungal infections have become a leading cause of human mortality due 64 
to their increasing frequency in immunocompromised populations and the low number 65 
of antifungals available (Shapiro et al., 2011). Chitosan has a great potential to be 66 
developed as an antifungal agent to treat diseases caused by human pathogenic fungi 67 
(Calamari et al., 2011; Peña et al., 2013; Kulikov et al., 2014 and Younes et al., 2014). 68 
Therefore, it is of vital importance to fully understand its mode of action. 69 
Chitosan causes plasma membrane permeabilization in N. crassa (Palma-Guerrero et 70 
al., 2009) and yeast (Jaime et al., 2012). Membrane fluidity is a key factor determining 71 
chitosan sensitivity in fungi (Palma-Guerrero et al., 2010). Cell energy and 72 
mitochondrial activity have also an important role in antifungal activity of chitosan 73 
(Palma-Guerrero et al., 2009; Zakrzewska et al., 2005). These processes are known to 74 
increase reactive oxygen species (ROS) as the main by-products (Kawaltowski et al., 75 
2009). A hyperoxidant unstable state is reached when ROS generation surpasses the 76 
antioxidant capacity of the cell. This ability could be associated with the presence of 77 
nutrients (a source of reducing power), which would help N. crassa to return from a 78 
hyperoxidant to a normal, less-oxidative state (Aguirre et al., 2005).  79 
In this study, we have analyzed the effect of the nutrient levels (carbon and nitrogen 80 
limitation) and the effect of the carbon source on sensitivity to chitosan of N. crassa and 81 
clinically important filamentous fungi and yeast human pathogens (Aspergillus 82 
fumigatus, Candida albicans, Cryptococcus spp.), besides pathogenic Candida spp. (C. 83 
krusei, C. glabrata and C. parapsilosis) resistant to currently used antifungals such as 84 
fluconazole or echinocandins. With this purpose, we have used a high-throughput 85 
spectrophotometrical methodology adapted from techniques standardized in the Clinical 86 
and Laboratory Standards Institute (NCCLS) of the USA (Clinical and Laboratory 87 
Standards Institute, 2008). Besides, we have determined in this work the production of 88 
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intracellular reactive oxygen species (ROS) by N. crassa and its relation to cell 89 
membrane permeabilization by chitosan under various carbon and nitrogen regimes. We 90 
have also evaluated the impact in chitosan sensitivity of N. crassa of replacing glucose 91 
for lactate as the main carbon source, since the latter is less energetically efficient. 92 
Nutrient status has a substantial effect on the susceptibility of fungal pathogens (e.g. C. 93 
albicans) to others antifungals (e.g. miconazole) (Ene et al., 2012a). Besides, C. 94 
albicans encounters carbon-poor conditions during host infection (Ramirez and Lorenz, 95 
2007). As a consequence, C. albicans displays an elaborated response in the host which 96 
includes activation of pathways needed to enable the use of alternative carbon sources. 97 
For this reason, gluconeogenesis, the glyoxylate cycle, and β-oxidation of fatty acids, 98 
have been shown to be required for full virulence in several pathogenic organisms 99 
(Lorenz and Fink, 2001; Prigneau et al., 2003). We have therefore determined the role 100 
of carbon and nitrogen status in C. albicans infecting an invertebrate model Galleria 101 
mellonella (Fuchs et al., 2010) treated with chitosan and artificially inoculated with the 102 
pathogen. Finally, the compatibility of chitosan with mammalian (including human) cell 103 
lines was investigated. These studies are a key step to develop chitosan as an antifungal 104 
agent in the future. 105 
2 Materials and methods 106 
2.1 Filamentous fungi and culture conditions.  107 
Fusarium proliferatum used in this study (CECT 20546) was obtained from the Spanish 108 
Type Culture Collection (CECT, Spain). Aspergillus fumigatus used in this study 109 
(ATCC16907) was obtained from the American Type Culture Collection (ATCC, 110 
USA). Hamigera avellanea (CECT 20819) was obtained from the Laboratory of 111 
Microbiology of the General University Hospital of Alicante (Spain) from a blood 112 
sample (hemoculture) of a neonate. Rhizopus stolonifer was a clinical strain from a 113 
periocular nasal fossa fat isolated by Dr. Arena (General Hospital Dr. Manuel Gea-114 
González, Mexico DF, Mexico). All pathogenic filamentous fungi were grown on 115 
potato dextrose agar (PDA) (Becton Dickinson and Company, USA) in 9 cm Petri 116 
dishes at 25 ºC. Neurospora crassa used in this study, was the wild-type strain 74-117 
OR23-IVA (FGSC #2489) kindly provided by the Fungal Genetics Stock Center 118 
(FGSC, USA). Neurospora crassa was grown on Vogel’s solid medium (MM) (1x 119 
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Vogel’s salts, 2% sucrose and 1.5% technical agar) in 9 cm Petri dishes at 25 ºC under 120 
continuous light for 5-7 days.   121 
2.2 Pathogenic yeasts. 122 
 Candida albicans (SN87) was kindly provided by Dr. Nislow (University of Toronto, 123 
Canada). Reference strains for antifungal susceptibility testing were: Candida krusei 124 
(ATCC6258), Candida glabrata (ATCC2001) and Candida parapsilosis (ATCC22019). 125 
Cryptococcus neoformans (ATCC3501) and Cryptococcus gattii (CBS11728) were also 126 
used.  Yeast were grown in 0.5x YPD broth medium pH 5 (0.5% bacto yeast extract, 127 
1% bacto peptone and 1% dextrose) for culture proliferation and 0.5x YPD agar (1.5% 128 
bacteriological agar) was used for stock cultures.  129 
2.3  Chitosan.  130 
A medium-size molecular weight chitosan (70 kDa) with 82.5% deacetylation degree 131 
(T8s) was from Marine Bio Products GmbH (Bremerhaven, Germany). Chitosan was 132 
dissolved in 0.25 M HCl under continuous stirring and the pH of the solution was 133 
adjusted to 5.6 with 1 M NaOH as described by Palma-Guerrero et al. (2008). The 134 
resulting solution was dialyzed against distilled water for salt removal, then autoclaved 135 
at 121 ºC for 20 min and finally it was stored at 4 ºC until used. 136 
2.4 Effect of nutrient limitation on growth kinetics of filamentous fungi and yeast.  137 
Experiments in liquid media were set up to evaluate growth kinetics of N. crassa, other 138 
filamentous fungi and yeast human pathogens. Conidia of filamentous fungi were 139 
obtained by adding 2 ml of 0.05% Tween-20 per Petri dish, from 8-to-10 day-old 140 
sporulated cultures. The resulting conidial suspensions were then filtered through 141 
Miracloth paper (Calbiochem) to remove hyphae fragments and adjusted to a final 142 
concentration of 106 conidia ml-1 with potato dextrose broth (PDB) (Becton Dickinson). 143 
 PDB (pH 5.6) was supplemented to include 0.1, 0.5, 1, 2, 5.8 and 10 g of glucose per 144 
liter (carbon (C): 0.04; 0.2; 0.4; 0.8; 2.32; 4 g l-1, respectively and nitrogen (N) contents: 145 
1.6x10-3; 7.8x10-3; 15.5x10-3; 0.03; 0.09 and 0.15 g l-1, respectively). Chitosan (0.5-146 
1000 µg ml-1) was added to these media and 200 µl per well were dispensed into 96 147 
well microtiter plates (Sterillin Ltd., Newport, UK). Plates were inoculated with N. 148 
crassa conidia (2x105 conidia per well) and incubated at 25 ºC under continuous light, 149 
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without shaking. The effect of chitosan on growth of filamentous fungi was evaluated 150 
by measuring daily for five days the optical density at 490 nm (OD490) (Clinical and 151 
Laboratory Standards Institute, 2008) in a GENiosTM multiwell spectrophotometer 152 
(Tecan, Männedorf, Switzerland).  153 
Regarding pathogenic yeast, overnight cultures grown at 30ºC in 0.5x YPD broth were 154 
used for experiments. Two μl of these cultures adjusted to a final OD595 of 0.0625 155 
(Burke, 2000) were added to each well of microtiter plates, containing 0-240 µg ml-1 of 156 
chitosan. Yeast were either grown at 30ºC (Cryptococcus spp.) or 37ºC (Candida spp.) 157 
and incubated as above and growth was spectrophotometrically monitored for 24 h. 158 
YPD was prepared by including increasing concentrations of glucose (0.1, 0.5, 1, 2, 5 159 
and 10 g l-1) as the main C source. YPD prepared with these glucose concentrations 160 
respectively included the following C (0.04; 0.2; 0.4; 0.8; 2; 4 g l-1) and N (0.015; 161 
0.074; 0.15; 0.3; 0.74 and 1.47 g l-1) contents. The N content of YPD was higher than 162 
that of media for filamentous fungi (e.g. PDB), since yeast require more N for their 163 
growth than the latter.  YPD was then amended with 0-240 µg ml-1 of chitosan. In order 164 
to evaluate the fungicidal effect of chitosan, we performed a spot assay by adding 2 µl 165 
of liquid cultures to plates with 0.5x YPD agar (1.5 % bacteriological agar) and these 166 
were incubated 48 h at 30 ºC.  All assays were carried out in triplicate.  167 
For the determination of carbon and nitrogen contents of PDB and YPD, aliquots of 168 
these nutrient media were processed in a TruSpec CN (Leco) elemental analyzer at the 169 
Common Research Facilities of the University of Alicante. 170 
2.5 Fungal membrane permeabilization.  171 
N. crassa conidia (106 conidia ml-1) were added to media containing several 172 
concentrations of C and N (see above), and supplemented with chitosan (1-50 µg ml-1). 173 
The mixture was then incubated at 25 ºC for 45 min under continuous shaking. Conidia 174 
were then stained with 30 nM Sytox Green® (Life Tech., USA) for 30 min in the dark to 175 
determine membrane permeabilization as in Thevissen et al. (1999). Fluorescence 176 
emission was evaluated in a Flow Cytometer (EPICS XL, Beckman Coulter) using 488 177 
nm and 520 nm as an excitation and emission wavelengths, respectively. Untreated 178 
controls to determine conidia auto-fluorescence were also included. Fifteen thousand 179 
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events per sample were recorded and the data analyzed using EXPO™ 32 MultiCOMP 180 
software (Beckman Coulter). All experiments were repeated twice. 181 
2.6 Intracellular ROS production.  182 
Intracellular ROS production was estimated fluorimetrically using 2’-7’ 183 
dichlorofluorescein diacetate (DCF) (Sigma, St. Louis, MO, USA). Neurospora crassa 184 
conidia (106 conidia ml-1) were inoculated in media with increasing concentrations of 185 
glucose, as previously described and amended with chitosan (1-50 µg ml-1). Conidia 186 
were then incubated at 25ºC under shaking (150 rpm) for 30 min. Afterwards, conidia 187 
were stained with 50 µg ml-1 DCF in DMSO (final concentration) and incubated for 2 h 188 
under shaking in the dark. Samples were placed in black microtiter plates (Sigma) and 189 
fluorescence was recorded with a GENiosTM multiwell reader, using a 490 nm 190 
excitation filter and a 535 nm emission filter (in triplicate). Untreated controls were 191 
incorporated to evaluate auto-fluorescence of conidia. Experiments were carried out in 192 
triplicate and all data sets obtained were checked using the Shapiro-Wilcoxon test. Data 193 
following a normal distribution were compared using ANOVA tests. The level of 194 
significance in all cases was 95%. All statistical analyses were performed with R 195 
version 2.15.1 (R Development Core Team).  196 
2.7 Time-course of ROS production and lethality in N. crassa treated with chitosan.  197 
Time-course experiments to evaluate ROS production in presence of chitosan were 198 
carried out under two nutritional regimes.  N. crassa conidia (107 conidia ml-1) were 199 
inoculated in either 2.5 g l-1 PDB (0.8 g l-1 C; 0.03 g l-1 N) or 12 g l-1 PDB (4 g l-1 C; 0.15 200 
g l-1 N). Conidia suspensions were amended with increasing concentrations of chitosan 201 
(2.5-100 µg ml-1) and then stained with DCF (see 2.6). Controls for auto-florescence of 202 
PDB and conidia were included. In addition, a positive ROS control (3% H2O2) was 203 
also included. All samples were dispensed into black microtiter plates and incubated (25 204 
ºC) in the multiwell plate reader. Fluorescence of samples (see above) was recorded 205 
every 10 min for 20 h to characterize ROS induction. Lethality of chitosan treatments 206 
was estimated with the spot assay as described, using GFS agar plates (1x MM salts, 2% 207 
sorbose, 0.05% glucose, 0.05% fructose and 1.5% bacteriological agar) (Carneiro et al., 208 
2012). 209 
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2.8 Effect of nutrient limitation with different carbon sources on N. crassa sensitivity 210 
to chitosan.  211 
Vogel’s minimal medium (MM) salts solution diluted 100 times (Vogel, 1956) was 212 
amended with 2, 5.8 and 10 g of either lactate or glucose per liter. To these media 213 
chitosan (1-50 µg ml-1) was added and N. crassa conidia inoculated as described (see 214 
2.4). N. crassa growth kinetics was evaluated spectrophotometrically as previously 215 
described. Each experiment was repeated three times. 216 
2.9 Chitosan cytotoxicity assay on mammalian cell lines.  217 
To evaluate chitosan cytotoxicity, we performed a methylthiazolyldiphenyl-tetrazolium 218 
bromide (MTT) (Sigma) colorimetric assay with human embryonic kidney HEK293 and 219 
the monkey fibroblast-like COS7 cell lines. Cells were seeded into 96-well plates, pre-220 
coated with 10 µg ml-1 of poly-L-lysine for HEK293, to obtain a cellular lawn, with 221 
three replicates at 5x103 and 20x103 cells/well each one. Cells were grown at 37 ºC and 222 
5% CO2 for 24 h in Dulbecco's Modified Eagle's medium  (DMEM; pH 7.5; Sigma) 223 
supplemented with 5% fetal bovine serum (FBS; Biobest), 1% L-glutamine, 1% 224 
penicillin/streptomycin (P/S; Thermo Scientific), 1% sodium pyruvate, 1% non-225 
essential amino acids for HEK293 cells and with 10% FBS, 1% L-glutamine, 1% P/S 226 
and 1% sodium pyruvate for COS7. After incubation, cells were treated with 100 µL of 227 
DMEM supplemented with different concentrations of chitosan (1, 5, 10, 25, 50, 100 228 
and 150 µg ml-1) in each well. Cells treated with DMSO and cells in wells with no 229 
growth medium were used as positive controls for cell death. We tested the toxicity 230 
after 24 h and proliferative activity after 24 h, 48 h and 72 h of treatments at 37ºC and 231 
5% CO2. With this purpose, the medium was removed from wells and 100 µL of 1 mg 232 
ml-1 MTT was added to each well. Plates were then incubated for 4 h at 37 ºC and 5% 233 
CO2 in the dark. The Formazan originated from MTT by the mitochondrial activity of 234 
living cells was solubilized in 100 µl of DMSO, and the absorbance at 570 nm was 235 
measured in a Benchmark Microplate Reader (Bio-Rad) (Kaushik et al., 2012; Yaris et 236 
al., 2013). All datasets obtained were analyzed using the Shapiro-Wilcoxon test. Data 237 
following a normal distribution were compared using ANOVA tests. The level of 238 
significance in all cases was 95%. All statistical analyses were performed with R 239 
version 2.15.1 (R Development Core Team). Cytotoxicity index (CI) was calculated as: 240 
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CI= (1-OD570 treated/OD570 control) x100 (Hongo et al., 1990). These experiments were 241 
carried out in triplicate. 242 
2.10 Inhibition and cytotoxicity evaluation of chitosan in mammalian peripheral 243 
blood lymphocyte cultures.  244 
Peripheral blood lymphocytes from five healthy donors were isolated by Ficoll-245 
Hypaque (HE Healthcare) density gradient and labeled with 5 µM carboxyfluorescein 246 
diacetate succinimidyl ester (CFSE, Sigma) in 1 ml of DMEM culture medium 247 
supplemented with 10% FBS and 1% P/S for 5 min, by using a standard protocol 248 
(Lyons, 2000). Cells (105 per replicate) were cultured for 5 days with and without 10 µg 249 
ml-1 phytohemagglutinin (PHA; Sigma), it necessary to stimulate lymphocyte 250 
proliferation, under different chitosan concentrations (0, 1, 5, 7.5, 25, 50, 75, 100, 200 251 
and 400 µg ml-1). Cell proliferation was then measured by flow cytometry (as above). 252 
Prior to flow cytometry analysis, cells were also labeled with 2 µg ml-1 propidium 253 
iodide (PI) (Sigma) to evaluate cell death, using 488 nm and 560 nm as excitation and 254 
detection wavelengths respectively. Five thousand lymphocytes per sample (chitosan 255 
dose) were acquired to measure cell proliferation and 10,000 events were recorded to 256 
measure cell death. Data were analyzed statistically, using One-way Anova and Tukey 257 
post-hoc tests. All statistical analyses were performed with R version 2.15.1 (R 258 
Development Core Team). Experiments were carried out in triplicate. 259 
2.11 Effect of chitosan on Galleria mellonella larvae infection by C. albicans. 260 
 Candida albicans was grown in 0.5x YPD (broth) overnight at 30 ºC with shaking. 261 
Forty eight µl of overnight cultures were diluted in either 0.25x or 0.5x YPD to obtain 262 
an inoculum with 3.1x106 cells ml-1. Chitosan was added to the media to reach final 263 
concentrations of 20-150 µg ml-1. Twenty larvae of G. mellonella (provided by Animal-264 
center S.C., Valencia, Spain) per treatment were injected (22 µl per larvae) using a 26G 265 
syringe (Terumo) as described in Fuchs et al. (2010). Larvae injected without chitosan 266 
or C. albicans were included as controls. Injected larvae were incubated at 30 ºC in the 267 
dark and their survival recorded daily. Mortality data were analyzed using the Kaplan-268 
Maier survival test (Martin-Bland and Altman, 1998). All data were analyzed 269 
statistically using SPSS statistics 17.0. This experiment was carried out in triplicate. 270 
3 RESULTS 271 
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3.1 Carbon and nitrogen limitation increase growth inhibition and membrane 272 
permeabilization caused by chitosan in N. crassa  273 
The effect of chitosan on growth of N. crassa depended directly on the C and N content 274 
of the medium used (Figs. 1A, 1C, 1E). Nutrient limitation increased growth inhibition 275 
and membrane permeabilization caused by chitosan in N. crassa (Figs 1B, 1D and 1F). 276 
Under low C (0.8 g l-1) and N (0.03 g l-1) content, chitosan minimal inhibitory 277 
concentration (MIC) was 5 µg ml-1 (Fig 1A). Under this nutrient level, a very low 278 
chitosan concentration (2.5 µg ml-1), caused partial membrane permeabilization and a 279 
25% growth reduction of N. crassa. This chitosan dose caused a slight shift in the peak 280 
of fluorescence in cells not stained towards Sytox emission wavelength, perhaps 281 
indicating subtle membrane damage. A higher chitosan dose (3.75 µg ml-1) resulted in 282 
the emission of Sytox fluorescence by all cells (Fig 1B), a fact that was associated with 283 
the disappearance of Sytox-unstained cells, indicative of massive plasma membrane 284 
permeabilization of all N. crassa conidia evaluated. This effect was more evident 285 
(sharper peaks) at higher concentrations of chitosan.  286 
When C (2.32 g l-1) and N (0.09 g l-1) levels in the medium were raised, N. crassa 287 
became more tolerant to chitosan, with a MIC of 10 µg ml-1 (Fig 1C). Under these 288 
conditions, plasma membrane permeabilization occurred at 10 µg ml-1 chitosan (Fig 289 
1D), indicating that plasma membrane was more resistant to chitosan permeabilization 290 
than at lower C and N levels. When we further increased nutrient (4 g l-1 of C and 0.15 g 291 
l-1 of N) contents, N. crassa stepped up its tolerance to chitosan to a MIC of 50 µg ml-1 292 
(Fig 1E). Under these nutrient levels, permeabilization of N. crassa conidia membrane 293 
was attained at an even higher chitosan dose of 30 µg ml-1 (Fig. 1F). The flow 294 
cytometry profile suggested that under these conditions plasma membrane 295 
permeabilization was an “all or none” process.  296 
Thus, nutrient (C and N) limitation enhances the chitosan antifungal effects and has a 297 
determinant role in chitosan-induced plasma membrane permeabilization in N. crassa. 298 
Under all nutritional statuses studied, membrane permeabilization occurred at chitosan 299 
concentrations when fungal growth was inhibited (Fig. 1). 300 
3.2 Chitosan increases intracellular ROS production in N. crassa 301 
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N. crassa intracellular ROS levels increased with chitosan concentration under various 302 
nutritional regimes (Fig. 2). At low levels of C (0.8 g l-1) and N (0.03 g l-1), a chitosan 303 
concentration of 2.5 µg ml-1, elicited a significant rise in ROS levels (Fig. 2A), which 304 
was coincident with the start of plasma membrane permeabilization (Fig. 1B). In 305 
contrast, at 5 µg ml-1, ROS production did not show significant differences compared to 306 
that elicited by 2.5 µg ml-1 chitosan (p-value< 0.05). At intermediate C and N 307 
concentrations (2.32 and 0.09 g l-1, respectively) in the medium, ROS levels raised 308 
steadily with chitosan dose, up to 5 µg ml-1 (Fig. 2B). Then, they remained stable up to 309 
10 µg ml-1 (MIC; Fig 1C). This concentration coincided with the start of plasma 310 
membrane permeabilization (see Fig. 1D). At high nutrient (C: 4 g l-1 and N: 0.15 g l-1)  311 
levels, a trend in ROS release similar to that found at intermediate C and N content 312 
(2.32 and 0.09 g l-1, respectively) could be observed (Fig. 2C). Membrane was 313 
permeabilized with 30 µg ml-1 of chitosan (see Fig. 1F), after maximum ROS 314 
production was achieved (10 µg ml-1). Therefore, intracellular oxidative stress seems to 315 
be an important response of N. crassa to chitosan. 316 
3.3 Chitosan fungicidal activity is associated with intracellular ROS induction in N. 317 
crassa 318 
A time-course study of ROS induction and mortality was carried out on N. crassa 319 
conidia treated with chitosan (Fig. 3). We found that under low nutrient conditions (see 320 
3.2) chitosan at 10 µg ml-1 elicited a steady ROS induction (1.5-fold compared to 321 
control) which caused full mortality of N. crassa conidia (Fig 3A and 3B). When 322 
nutrients were raised (4 g l-1 C and 0.15 g l-1 N) chitosan above 30 µg ml-1 caused ROS 323 
induction (2-fold compared to control) and N. crassa full mortality (Fig 3C and 3D).  In 324 
contrast, low chitosan concentrations had low (small spots formation) or no effect on N. 325 
crassa mortality at the two nutrient regimes tested. Control conidia displayed a ROS 326 
induction similar to that found at low chitosan doses. 327 
3.4 Chitosan exhibits greater antifungal activity to N. crassa with lactate instead of 328 
glucose as main carbon source 329 
A nutrient (C and N) reduction when lactate replaced glucose as the main carbon source 330 
enhanced chitosan antifungal activity in N. crassa (Fig. 4). At low concentrations of C 331 
and N when 2 g l-1 glucose was used as the main C source (C, 0.8 g l-1; N, 0.0014 g l-1), 332 
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N. crassa was less sensitive to chitosan (MIC 10 µg ml-1, Fig. 4A), than when an 333 
equivalent concentration of lactate was used instead of glucose (MIC, 2.5 µg ml-1, Fig. 334 
4B). On the other hand, intermediate concentrations of C and N (5.8 g l-1glucose) (C, 335 
2.32 g l-1; N, 0.004 g l-1) elicited no changes in N. crassa sensitivity to chitosan (MIC 10 336 
µg ml-1, Fig. 4C). Replacing glucose by lactate resulted in an increase of N. crassa 337 
sensitivity to chitosan (MIC 2.5 µg ml-1, Fig. 4D). Although increasing nutrient content 338 
when lactate was used as the main C source did not change N. crassa sensitivity to 339 
chitosan (MIC 2.5 µg ml-1), growth of this fungus increased by ca. two-fold with respect 340 
to that at 2 g l-1 of lactate (Fig. 4B and 4D). An increase in C and N levels (C, 4 g l-1; N, 341 
0.007 g l-1) in the medium (10 g l-1 glucose) diminished N. crassa sensitivity to chitosan 342 
(MIC 17.5 µg ml-1) (Fig. 4E) and under these conditions, glucose replacement by lactate 343 
increased chitosan sensitivity of the fungus (MIC 5 µg ml-1) (Fig. 4F). These results 344 
indicate that when lactate was used instead of glucose as the main carbon source, 345 
chitosan antifungal activity on N. crassa was enhanced by ca. 4 times. 346 
3.5 Carbon and nitrogen limitation increase chitosan susceptibility in filamentous 347 
fungi and yeast human pathogens 348 
In view of our previous results on the enhancement of chitosan antifungal effect by 349 
nutrient (C and N) limitation on N. crassa, we performed similar tests on a wide variety 350 
of clinically important human fungal pathogens (Fig. 5). Carbon (0.4 g l-1) and nitrogen 351 
(0.016 g l-1) concentrations in the growth medium were set to normal value of human 352 
blood glucose content (glycemia). At these nutrient contents, chitosan (2.5 µg ml-1) 353 
caused a moderate (ca. 25%) growth inhibition in F. proliferatum with MIC and 354 
minimal fungicidal concentration (MFC) of 5 µg ml-1 (Fig. 5A, Table 1). Under the 355 
same C and N contents, chitosan (above 40 µg ml-1) caused growth inhibition on A. 356 
fumigatus during the first 48 h, but later on (after 72 h) the fungus resumed growth 357 
(Table 1 and Suppl. Fig 1L). At the same C level and with 0.15 g l-1 of N, chitosan MIC 358 
was 10 µg ml-1 for C. albicans (Fig. 5D) and 20 µg ml-1 for C. krusei (fluconazole 359 
resistant strain, Suppl. Fig. 2F) and C. neoformans (Suppl. Fig. 2P). MFC for C. 360 
albicans and C. krusei was 20 µg ml-1 (Table 1).  361 
A reduction of carbon (0.2 g l-1) (similar to low levels of glucose in blood, 362 
hypoglycemia) and nitrogen (0.074 g l-1) in the culture medium increased the chitosan 363 
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antifungal effects (Table 1). For instance, for C. albicans chitosan MIC was again 10 µg 364 
ml-1, but MFC became reduced (10 µg ml-1) with respect to the value found at higher 365 
nutrient content. At severe C (0.04 g l-1) and N (0.015 g l-1) limitation chitosan MIC was 366 
further reduced to 5 µg ml-1 (Table 1). An increase in sensitivity to chitosan with 367 
nutrient limitation was also found for the rest of fungal human pathogens tested (Table 368 
1). 369 
Conversely, high levels of C and N reduced chitosan antifungal activity on the fungi 370 
(Fig. 5, Table 1 and Suppl. Figs. 1, 2). For instance, C. albicans growing from 0.8 g l-1 371 
of C and 0.3 of  N to 4 g l-1 of C and 1.5 g l-1 of  N, increased chitosan MIC from 20 to 372 
80 µg ml-1 (Table 1) . The fungicidal activity of chitosan at low levels of nutrients 373 
increased respect to that at high nutrient content in Candida spp. (Table 1, Fig. 6). 374 
Furthermore, other Candida spp. (C. krusei, C. glabrata and C. parapsilosis) also 375 
proved to be sensitive to chitosan (Table 1, Suppl. Fig. 2). This pattern was also found 376 
in C. neoformans and C. gattii (Table 1, Suppl. Fig. 2), both yeasts showed less chitosan 377 
antifungal sensitivity at high than at low nutritional (C and N) levels. Regarding 378 
filamentous fungal pathogens, F. proliferatum (Table 1) and H. avellanea (Suppl. Fig. 379 
1) were sensitive to chitosan and their MICs increased from 7.5 and 5 µg ml-1, from 0.8 380 
g l-1 C and 0.03 g l-1 N to 40 and 30 µg ml-1 at 4 g l-1 C and 0.15 g l-1 N, respectively 381 
(Table 1). On the contrary, A. fumigatus and R. stolonifer were chitosan insensitive at 382 
all these high C and N levels. These fungi reduced its growth at high concentration of 383 
chitosan, but this compound never was fungicide for both species. 384 
3.6 Chitosan does not affect growth of HEK293 and COS7 cell lines 385 
Chitosan was tested on two mammalian cell lines (HEK293 and COS7; Fig. 7). No 386 
effect on cell viability was found after 24 h (Fig. 7A and 7B). At the two cell densities 387 
tested, chitosan at 1-150 µg ml-1 displayed no differences on cell viability (P< 0.05) 388 
with respect to untreated controls. On the contrary, virtually full mortality was found 389 
when cells were either dried (physical disturbance) or treated with DMSO (chemical 390 
disturbance). The cytotoxicity index (CI) of chitosan did not exceed 50% of inhibitory 391 
concentration (IC50) (Suppl. Table 1).  392 
Chitosan cytotoxicity was evaluated over time in order to determine its effect on cell 393 
proliferation. Chitosan showed no effect on cell proliferation at 48 h (Figs. 7C and 7D) 394 
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for all concentrations tested, except at 150 µg ml-1. At this concentration, COS7 (CI 395 
value 88 at 72 h) but especially HEK293 cells, were sensitive to chitosan (CI value, 61 396 
at 48h) (Suppl. Table 2). 397 
3.7 Chitosan has a low effect on human lymphocytes 398 
The effect of chitosan on mortality and proliferation of human lymphocytes was 399 
evaluated (Fig. 8). Chitosan cytotoxicity on human lymphocytes never reached values 400 
higher than 20% (7.5 µg ml-1) of that found in untreated control cells (Fig. 8A). No clear 401 
correlation between chitosan concentrations and cytotoxicity was observed. For 402 
instance, with the high range of chitosan concentration tested (25-400 µg ml-1), only 50 403 
and 400 µg ml-1 had an effect on cell death, but cells treated with chitosan at 75-200 µg 404 
ml-1 showed no significantly differences in their viability compared to controls (Fig. 405 
8A). 406 
A slight reduction in lymphocyte proliferation (IC30, 28%) was found when chitosan 407 
was added at 25 µg ml-1 (Fig. 8B). However, differences in lymphocyte proliferation in 408 
cells treated with chitosan were found not statistically different respect to controls 409 
(without chitosan). 410 
3.8 Nutrient limitation promotes chitosan reduction of C. albicans virulence to G. 411 
mellonella 412 
Chitosan significantly reduced C. albicans virulence on larvae of the moth G. 413 
mellonella measured as cumulative survival (Fig. 9). C. albicans caused high larvae 414 
mortality at 2 g l-1 C and 0.74 g l-1 N in the medium, since all infected larvae without 415 
chitosan (positive controls) died within 24 h (Fig. 9B). Interestingly, chitosan increased 416 
G. mellonella larvae survival in a concentration-dependent fashion under these 417 
conditions. After 48 h, ca. 20% of the larvae treated with 20 µg ml-1 of chitosan 418 
survived and at higher concentrations of chitosan (100 µg ml-1) larval survival was close 419 
to 100%, the mortality confidence interval (152-262 h) showed significant differences 420 
(p< 0.05) compared to that of controls. 421 
When nutrient content was increased (C, 4 g l-1 and N, 0.15 g l-1) C. albicans virulence 422 
on G. mellonella was reduced (Fig. 9D). Therefore, the effect of chitosan on C. albicans 423 
virulence was less evident than that at low concentrations of nutrients. After 48 h, a 65% 424 
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survival was achieved at 100 µg ml-1 compared to 40% survival at 40 µg ml-1 chitosan. 425 
Under different nutrient regimes, non-injected larvae exhibited mortalities similar to 426 
those of controls when they were injected with chitosan only and no C. albicans (Fig. 427 
9A and 9C). 428 
4 DISCUSSION 429 
We here demonstrated that nutrient (C and N) limitation increased N. crassa sensitivity 430 
to chitosan. Some features associated with fungal nutrient deprivation (hyphal 431 
fragmentation, ammonium release and increase in extracellular hydrolytic activities) 432 
(Nitsche et al., 2012; Szilágyi et al., 2013) could modify N. crassa cell wall architecture 433 
making it more permeable to chitosan. Under these conditions chitosan could then reach 434 
more easily the plasma membrane, facilitating its permeabilization. Alternatively, C and 435 
N limitation could result in lack of energy necessary for the cell wall and for plasma 436 
membrane repair after chitosan damage.  437 
We have been able to link the increase in chitosan sensitivity due to C and N limitation 438 
to plasma membrane permeabilization and intracellular ROS production. This finding, 439 
reported for the first time, would explain why sodium azide, which uncouples oxidative 440 
metabolism and prevents ROS production, protects N. crassa from chitosan by 441 
preventing membrane permeabilization (Palma-Guerrero et al., 2009; Carneiro et al., 442 
2012). In the present work, we also demonstrate that chitosan fungicidal activity to 443 
which N. crassa is sensitive is associated with the induction of intracellular ROS by this 444 
fungus (a chitosan sensitive fungus). ROS could cause membrane permeabilization by 445 
means of lipid peroxidation, mostly to polyunsaturated fatty acids (Howlett and Avery, 446 
1997), which are very abundant in N. crassa and other chitosan-sensitive fungi (Palma-447 
Guerrero et al., 2010). At chitosan concentrations where complete membrane 448 
permeabilization took place, ROS production decreased. Mitochondrial membrane 449 
permeabilization would cause uncoupling of the electron transport chain, the main 450 
source of intracellular ROS (Kowaltowski et al., 2009; Carneiro et al., 2012), this 451 
explaining our experimental results. ROS production is a by-product from processes 452 
such as programmed cell death, abiotic stress and systemic signaling in filamentous 453 
fungi and plants (Mittler, 2002; Aguirre et al., 2005; Mittler et al., 2011). ROS have also 454 
been associated with the mode of action of currently used antifungals such as 455 
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miconazole (Ene et al., 2012a). We have found in this work that when N. crassa was 456 
released from C and N limitation, chitosan antifungal activity was reduced. High 457 
nutrient supply would increase metabolic rate and generate ROS as by-product. 458 
However, at the same time a high amount of antioxidant enzymes could be synthesized 459 
in order to scavenge ROS excess and prevent cell damage (Yan et al., 2006). An 460 
alternative way to reduce the hyperoxidant state in fungi treated with chitosan would be 461 
to increase reducing power by supplying a higher C and N content to the growth 462 
medium. In this regard, when lactate was used as a main carbon source instead of 463 
glucose, C and N limitation increased N. crassa sensitivity to chitosan to a larger extent 464 
(ca. 4-fold) compared to glucose. Since chitosan antifungal activity depends directly on 465 
the energetic status of the cell, our result could be explained because lactate is able to 466 
provide less reducing power and it is less efficient energetically than glucose. 467 
The nutritional status also affected the sensitivity of filamentous fungi and yeast 468 
pathogens to chitosan. This increase in sensitivity with nutrient limitation has also been 469 
found in C. albicans for other antifungals (Ene et al., 2012a; Ene et al., 2012b).  470 
Candida spp. have shown a high sensitivity to chitosan in previous studies (Peña et al., 471 
2013; Kulikov et al., 2014). F. proliferatum is an important human pathogen which 472 
causes mycoses in immunosuppressed patients (Summerbell et al., 1988) which was 473 
found in our study even more sensitive to chitosan than Candida spp. The plant 474 
pathogen F. oxysporum f. sp. radicis-lycopersici was previously found to be highly 475 
sensitive to chitosan (Palma-Guerrero et al., 2008). We have also found Cryptococcus 476 
spp. to be sensitive to chitosan. This polymer has been found to be a cell wall 477 
component of C. neoformans and a requirement for virulence and persistence in 478 
mammalian hosts of the fungus (Baker et al., 2007; Baker et al., 2011). Chitosan added 479 
exogenously to the growth medium could generate a chitosan excess which would 480 
determine its antifungal effect to Cryptococcus spp. found in our work. As for the other 481 
human pathogens, the C and N status influence in the same direction chitosan antifungal 482 
activity on C. neoformans and C. gattii. 483 
Most chitosan concentrations tested in our study were non-toxic for mammalian cells 484 
(Qi et al., 2005). We found a low cytotoxicity of chitosan on lymphocytes, but no effect 485 
on their proliferation as found in other studies (Borges et al., 2007). In our study, we 486 
have shown that chitosan reduced C. albicans virulence on G. mellonella. This 487 
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experimental insect host has been previously used to evaluate the effect of other 488 
antimicrobials on Candida spp. virulence (Cowen et al., 2009; Mesa-Arango et al., 489 
2013). Besides, we have also reported that lowering nutrients increased this inhibitory 490 
effect of chitosan on C. albicans virulence. Future studies should aim to investigate the 491 
basis of the reduction of virulence and the increase of antifungal effect of chitosan 492 
associated with C and N limitation, because C. albicans encounters carbon-poor 493 
conditions during infection and growth in its hosts (Lorenz and Fink, 2001). To this 494 
respect, alternative carbon sources are known to strongly influence C. albicans 495 
virulence and its susceptibility to antifungal drugs (Ene et al., 2012a).  496 
In conclusion, we have shown that nutrient (C and N) status and ROS are key factors of 497 
chitosan antifungal mode of action. The mechanisms by which both factors cause fungal 498 
membrane permeabilization and death should be further investigated. To this respect, N. 499 
crassa, high levels of ROS are known to activate the mechanisms which trigger 500 
programmed cell death (Castro et al., 2008). The liaison between ROS production, 501 
membrane permeabilization and its implication in membrane lipid peroxidation should 502 
be established by evaluating this process under diverse nutrient (C and N) conditions 503 
and chitosan doses. Other alternative mechanisms by which chitosan permeabilizes 504 
membranes and kills fungal cells cannot be excluded. Perhaps a balance between ROS 505 
detoxification and antioxidant mechanisms could be the key to understand the 506 
differential sensitivity of fungi to chitosan. Future studies should also contemplate the 507 
effect of ROS scavenging nutrients (Chen and Dickman, 2005) and the expression of 508 
ROS detoxification enzymes on chitosan antifungal activity. Our results illustrate that 509 
chitosan is a promising antifungal agent towards relevant human fungal pathogens 510 
whose potency can be enhanced by modifying the nutritional status in its environment. 511 
The low toxicity on mammalian cells opens new opportunities for the clinical use of 512 
chitosan as an antifungal alone or in combination with conventional antifungals. 513 
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FIGURE LEGENDS 662 
Figure 1. Effect of nutrient (C and N) content on chitosan antifungal activity on 663 
growth and membrane permeabilization in N. crassa. (A, C and E) show the effect 664 
of chitosan on growth kinetics and (B, D and F), the evaluation of cell membrane 665 
permeabilization by Sytox Green© in N. crassa, under increasing nutrient (C and N) 666 
content of the culture medium: 0.8 C; 0.03 N g l-1 (A, B), 2.32 C; 0.09 N g l-1 (C, D) 667 
and 4 C; 0.15 N g l-1 (E, F), respectively. Chitosan concentrations used are shown in 668 
each graph. (A, C and E) graph values are the average of 4 estimations with their 669 
standard error (SE).  (B, D and F) graphs represent the accumulated values from 15 670 
000 events per each single curve. 671 
 Figure 2. Intracellular reactive oxygen species (ROS) production by N. crassa 672 
conidia treated with chitosan under different nutrient (C and N) statuses. ROS 673 
production was determined by DCF fluorescence with increasing chitosan 674 
concentrations (0-50 µg ml-1) under 3 nutritional (C and N) regimes: (A) 0.8 C; 0.03 675 
N g l-1 (B), 2.32 C; 0.09 N g l-1 and (C) 4 C; 0.15 N g l-1. Different letters indicate 676 
significant differences (P< 0.05). Values are the average of 4 estimations with their 677 
standard error (SE). 678 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
Figure 3. Chitosan elicitation of ROS production and fungicidal activity in N. 679 
crassa conidia under two nutrient (C and N) statuses. (A, B)  C and N low content 680 
(0.8 C; 0.03 N g l-1) and (C, D) C and N high content (4 C; 0.15 N g l-1) media. (A, 681 
C) ROS induction. (B, D) Serial dilutions (from left to right) of conidial suspensions 682 
of  N. crassa wild-type strain were spotted and incubated on GFS agar plates at 25ºC 683 
for 48h. Values are the average of 4 estimations as above. 684 
Figure 4. Effect of carbon source (lactate vs. glucose) on sensitivity of N. crassa to 685 
chitosan under various nutrient (C and N) regimes. (A, C, E) 2, 5.8 and 10 g l-1 686 
glucose, respectively, in 1/100 Vogel’s salts solution. (B, D, F) 2, 5.8 and 10 g l-1 687 
lactate, respectively, in 1/100 Vogel’s salts solution. Nutrient (C and N) content of 688 
culture media: (A, B) 0.8 C; 0.0014 N g l-1, (C, D) 2.32 C; 0.004 N g l-1 and (E, F) 4 689 
C; 0.007 N g l-1. Values are the average of 4 estimations as above. 690 
Figure 5. Effect of chitosan on growth kinetics of relevant filamentous fungi and 691 
yeast pathogens under different nutritional regimes. (A, B, C) Fusarium 692 
proliferatum, (D, E, F) and Candida albicans. Nutrient (C and N) contents of 693 
medium for F. proliferatum were: (A) 0.4 C; 0.016 N g l-1, (B) 0.8 C; 0.03 N g l-1 694 
and (C) 4 C; 0.15 N g l-1. For C. albicans: (D) 0.4 C; 0.15 N g l-1, (E) 0.8 C; 0.3 N g 695 
l-1 and (F) 4 C; 1.5 N g l-1. Values are the average of 4 estimations with their 696 
standard error (SE). 697 
Figure 6. Chitosan susceptibility profiles of C. albicans determined by spot assay. 698 
C. albicans cells were cultured on YPD agar plates. (A) YPD 0.25x (0.8-0.3 g l-1 C 699 
and N content), (B) YPD 0.5x (4 C; 1.5 N g L-1, C and N contents). Aliquots of 2 µl 700 
from 24 h cell cultures supplemented with chitosan were diluted serially (10-fold) 701 
and spotted on the YPD plates with chitosan (0-150 µg ml-1). Growth differences 702 
were detected after 48 h incubation at 30 ºC. 703 
Figure 7. Chitosan effects on viability and proliferation of mammalian cell lines. 704 
(A, C) HEK293 and (B, D) COS7 human and monkey cell lines, respectively. (A, 705 
B) Cytotoxic effect of chitosan determined at 24 h. (C, D) Effect of chitosan on cell 706 
proliferation at 24, 48 and 72 h. Both parameters were measured using the MTT 707 
assay (OD570). Different letters (a-d) indicate significant differences (P< 0.05). 708 
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Statistical analyses were carried out independently for each experiment (eg. number 709 
of cells for cell viability or time for cell proliferation). 710 
Figure 8. Effect of chitosan on human lymphocytes. (A) Lymphocyte mortality 711 
estimated by propidium iodide staining after flow cytometry. (B) Lymphocyte 712 
proliferation determined with the CFSE cell proliferation kit after flow cytometry. 713 
Asterisks indicate significant differences (P< 0.05) in lymphocyte mortality. Line 714 
indicates the half maximal inhibitory concentration (IC50) for chitosan. Values are 715 
the average ±SE from 6 estimations made on independent lymphocyte populations.  716 
Figure 9. Effect of chitosan on virulence of Candida albicans on Galleria 717 
mellonella under different nutrient (C and N) regimes in YPD medium. (A) and (C) 718 
YPD 0.25x (0.8 C; 0.3 N g l-1) and YPD 0.5x (4 C; 1.5 N g l-1) respectively  without 719 
C. albicans (mortality by chitosan). (B) and (D) YPD 0.25x (0.8 C; 0.3 N g l-1) and 720 
YPD 0.5x (4 C; 1.5 N g l-1) respectively, inoculated with C. albicans. Mortality 721 
confidence interval 152-262 h for 100 µg ml-1 of chitosan (p< 0.05). Treatments: 722 
Controls= no chitosan; chi= chitosan concentrations. N/P= Galleria mellonella 723 
larvae non-injected (no treatment) at all.  724 
 725 
Table 1. Antifungal effect of chitosan on important species of filamentous fungi and 726 
yeast human pathogens under different nutrient (C and N) conditions. Minimal 727 
inhibitory concentration (MIC; µg ml-1) and minimal fungicidal concentration 728 
(MFC; µg ml-1) for chitosan on the fungal pathogens species are given. 729 
 730 
Supplementary Figure 1. Effect of chitosan on growth of filamentous fungal 731 
human pathogens under different nutrient (C and N) conditions. (A, B, C) Hamigera 732 
avellanea and (D, E, F) Rhizopus stolonifer. C and N contents of the medium were: 733 
(A, D) 0.8 C; 0.031 N g l-1, (B, E) 2.32 C; 0.087 N g l-1, (C, F) 4 C; 0.15 N g l-1, 734 
respectively. (G, H, I) Fusarium proliferatum. C and N contents of the medium 735 
were: (G) 0.04 C; 0.0015 N g l-1, (H) 0.2 C; 0.007 N g l-1, (I) 4 C 0.15; N g l-1 and 736 
(J-O) Aspergillus fumigatus. C and N contents of the medium were: (J) 0.04 C; 737 
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0.0015 N g l-1, (K) 0.2 C; 0.007 N g l-1, (L) 0.4 C; 0.015 N g l-1, (M) 0.8 C; 0.031 N 738 
g l-1, (N) 2.32 C; 0.087 N g l-1, (O) 4 C; 0.15 N g l-1, respectively. 739 
Supplementary Figure 2. Chitosan effect on growth of yeast human pathogens 740 
under different nutrient (C and N) conditions. (A, B, C) Candida albicans. C and N 741 
contents of the medium were: (A) 0.04 C; 0.015 N g l-1, (B) 0.2 C; 0.074 N g l-1, (C) 742 
2 C; 0.74 N g l-1, respectively. (D, E, F, G, H, I) Candida krusei. C and N contents 743 
of the medium were: (D) 0.04 C; 0.015 N g  l-1, (E) 0.2 C; 0.074 N g l-1, (F) 0.4 C; 744 
0.15 N  g l-1,(G) 0.8 C; 0.3 N g l-1, (H) 2 C; 0.74 N g l-1, (I) 4 C 1.5 N g l-1, 745 
respectively. (J, K) Candida glabrata and (L, M) Candida parapsilosis. C and N 746 
contents of the medium were:  (J, L) 2 C; 0.74 N g l-1 and (K, M) 4 C; 1.5 N g l-1. 747 
(N-U) Cryptococcus spp.: Cryptococcus neoformans. C and N contents of the 748 
medium were:  (N) 0.04 C; 0.015 N g  l-1, (O) 0.2 C; 0.074 N g l-1, (P) 0.4 C; 0.15 N  749 
g l-1,(Q) 0.8 C; 0.3 N g l-1, (R) 2 C; 0.74 N g l-1, (S) 4 C; 1.5 N g l-1 and 750 
Cryptococcus gattii. C and N contents of medium were: (T) 2 C; 0.74 N g l-1, (U) 4 751 
C; 1.5 N g l-1. 752 
 753 
Supplementary Table 1. Effect of chitosan on human HEK293 and monkey COS7 754 
cell lines. The effect was estimated using a cytotoxic index defined as (1-OD470treated-755 
OD470controls)x100. 756 
Supplementary Table 2. Effect of chitosan on proliferation of human HEK293 and 757 
monkey COS7 cell lines. The effect was estimated using a cytotoxic index defined 758 
as (1- OD470treated-OD470controls)x100. 759 
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Table 1. Antifungal effect of chitosan on important species of filamentous fungi and yeast human pathogens under different nutrient (C and N) conditions. 
Minimal inhibitory concentration (MIC; µg ml-1) and minimal fungicidal concentration (MFC; µg ml-1) for chitosan on the fungal pathogens species are given. 
 [C and N] (g L-1) 0.04/0.0015¥ 0.2/0.007¥ 0.4/0.015¥ 0.8/0.031¥ 2.32/0.087¥ 4/0.15¥ 
Filamentous fungi 24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h 
Fusarium 
proliferatum 2.5 2.5 2.5* 2.5 2.5 2.5* 2.5 5 5* 5 7.5 7.5* 10 20 20* 20 30 40* 
Hamigera avellanea          2.5 5 5* 10 20 20* 10 20 30* 
Aspergillus fumigatus 1 1 1000 1 5 1000 1 40 1000 100 1000 1000 100 ni ni 1000 ni ni 
Rhizopus stolonifer          100 ni ni ni  ni ni ni  ni ni 
[C and N] (g L-1) 0.04/0.015¥ 0.2/0.074¥ 0.4/0.15¥ 0.8/0.3¥ 2/0.74¥ 4/1.5¥ 
Yeast 6 h 12 h  24 h 6 h 12 h  24 h 6 h 12h  24h 6h 12h  24h 6h 12h  24h 6h 12h  24h 
Candida albicans 5 5 
5 
(10) 5 10 10* 10 10 
10 
(20) 20 20 
20 
(40) 20 40 
40 
(80) 40 80 
80 
(100) 
Candida parapsilosis             40 40 40* 40 110 110* 
Candida krusei 5 5 10* 5 10 10* 10 20 20* 20 20 
20 
(40) 40 40 80* 40 80 80 
Candida glabrata             20 80 80* 100 110 240 
Cryptococcus 
neoformans 5 5 5 5 5 5 10 20 20 20 40 40 40 40 40 40 80 100 
Cryptococcus gatti             10 20 80 2.5 110 160 
                   *  Indicates taht chitosan MIC and MFC were coincided 
( )
 Indicates that chitosan inhibitory concentration was fungicidal (MFC) 
¥
 Nutrients (C and N) was included in PDB medium at 0.04C-0.0015N g L-1, 0.2C-0.007N g L-1, 0.4C-0.015N  g L-1, 0.8C-0.031N g L-1, 2.32C-0.087N g L-1, 4C-
0.15N g L-1. 
§
 Nutrients (C and N) was included in YPD medium at  0.04C-0.015N g L-1, 0.2C-0.074N g L-1, 0.4C-0.15N  g L-1, 0.8C-0.3N g L-1, 2C-0.74N     g L-1, 4C-1.5N g L-
1
. 
"ni" non-inhibitory 
                  
"-" not tested 
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HEK293 COS7 
  
Cells per well Cells per well 
 
 
  5 000 20 000 5 000 20 000 
Chitosan 
(µg/ml) 
1 -4.15 26.86 -4.05 -5.40 
5 -9.41 20.78 -26.86 -5.87 
10 -1.42 17.76 -24.38 0.53 
25 -3.54 9.22 -23.06 1.45 
50 -4.66 17.49 -25.45 -1.76 
100 -25.71 9.82 -9.59 -3.50 
150 -26.82 14.39 -13.47 -8.74 
 
 
DMSO 70.34 94.49 68.51 91.60 
 
 
Dried 
cells 65.69 90.39 61.16 87.47 
      The horizontal dashed line separates cytotoxic index values 
>IC50 
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HEK293 COS7 
 
Time (h) Time (h) 
  24h 48h 72h 24h 48h 72h 
Chitosan  
(µg/ml) 
1 5.32 -24.32 -6.65 -1.43 -13.23 -8.57 
5 1.03 -37.84 -15.29 8.20 12.17 19.31 
10 10.38 -35.37 2.47 5.79 -2.65 25.49 
25 7.63 -42.97 -5.56 2.41 -9.07 2.72 
50 16.21 -22.44 -6.84 -10.60 -23.36 -11.75 
100 13.72 -32.36 -1.12 1.05 -3.19 -8.05 
150 24.96 61.07 96.36 1.05 21.77 87.66 
  DMSO 58.40 89.77 96.02 78.35 87.21 92.30 
  
Dried 
cells 63.72 84.19 93.59 63.61 76.15 84.04 
        The horizontal dashed line separates cytotoxic index values 
>IC50 
    
